152 related articles for article (PubMed ID: 37752742)
1. Effects of door-to-tolvaptan time on short-term clinical outcome in patients with acute heart failure.
Nomura R; Morishita T; Sato Y; Aoyama D; Shimizu T; Uzui H; Nakano A; Tada H
ESC Heart Fail; 2023 Dec; 10(6):3573-3581. PubMed ID: 37752742
[TBL] [Abstract][Full Text] [Related]
2. Clinical effectiveness and adverse events associated with tolvaptan in patients above 90 years of age with acute decompensated heart failure.
Morita Y; Endo A; Kagawa Y; Yamaguchi K; Sato H; Ouchi T; Watanabe N; Tanabe K
Heart Vessels; 2021 Jun; 36(6):836-843. PubMed ID: 33527152
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of Tolvaptan in Patients More Than 90 Years Old With Acute Heart Failure.
Sato Y; Uzui H; Mukai M; Shiomi Y; Hasegawa K; Ikeda H; Tama N; Fukuoka Y; Morishita T; Ishida K; Kaseno K; Miyazaki S; Nakano A; Tada H
J Cardiovasc Pharmacol Ther; 2020 Jan; 25(1):47-56. PubMed ID: 31280620
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of Tolvaptan in Patients Hospitalized With Acute Heart Failure.
Felker GM; Mentz RJ; Cole RT; Adams KF; Egnaczyk GF; Fiuzat M; Patel CB; Echols M; Khouri MG; Tauras JM; Gupta D; Monds P; Roberts R; O'Connor CM
J Am Coll Cardiol; 2017 Mar; 69(11):1399-1406. PubMed ID: 27654854
[TBL] [Abstract][Full Text] [Related]
5. Short-Term Effects of Tolvaptan in Patients With Acute Heart Failure and Volume Overload.
Konstam MA; Kiernan M; Chandler A; Dhingra R; Mody FV; Eisen H; Haught WH; Wagoner L; Gupta D; Patten R; Gordon P; Korr K; Fileccia R; Pressler SJ; Gregory D; Wedge P; Dowling D; Romeling M; Konstam JM; Massaro JM; Udelson JE;
J Am Coll Cardiol; 2017 Mar; 69(11):1409-1419. PubMed ID: 28302292
[TBL] [Abstract][Full Text] [Related]
6. Early use of V2 receptor antagonists is associated with a shorter hospital stay and reduction in in-hospital death in patients with decompensated heart failure.
Matsukawa R; Kubota T; Okabe M; Yamamoto Y
Heart Vessels; 2016 Oct; 31(10):1650-8. PubMed ID: 26676672
[TBL] [Abstract][Full Text] [Related]
7. Use of tolvaptan vs. furosemide in older patients with heart failure : Meta-analysis of randomized controlled trials.
Huang WL; Yang Y; Yang J; Yang J; Wang HB; Xiong XL; Zhang YF
Herz; 2018 Jun; 43(4):338-345. PubMed ID: 28523370
[TBL] [Abstract][Full Text] [Related]
8. Early administration of tolvaptan preserves renal function in elderly patients with acute decompensated heart failure.
Kimura K; Momose T; Hasegawa T; Morita T; Misawa T; Motoki H; Izawa A; Ikeda U
J Cardiol; 2016 May; 67(5):399-405. PubMed ID: 26692119
[TBL] [Abstract][Full Text] [Related]
9. Tolvaptan Reduces the Risk of Worsening Renal Function in Patients With Acute Decompensated Heart Failure and Preserved Left Ventricular Ejection Fraction - Prospective Randomized Controlled Study.
Tamaki S; Sato Y; Yamada T; Morita T; Furukawa Y; Iwasaki Y; Kawasaki M; Kikuchi A; Kondo T; Ozaki T; Seo M; Ikeda I; Fukuhara E; Abe M; Nakamura J; Fukunami M
Circ J; 2017 Apr; 81(5):740-747. PubMed ID: 28202885
[TBL] [Abstract][Full Text] [Related]
10. Early treatment with tolvaptan improves diuretic response in acute heart failure with renal dysfunction.
Matsue Y; Ter Maaten JM; Suzuki M; Torii S; Yamaguchi S; Fukamizu S; Ono Y; Fujii H; Kitai T; Nishioka T; Sugi K; Onishi Y; Noda M; Kagiyama N; Satoh Y; Yoshida K; van der Meer P; Damman K; Voors AA; Goldsmith SR
Clin Res Cardiol; 2017 Oct; 106(10):802-812. PubMed ID: 28540483
[TBL] [Abstract][Full Text] [Related]
11. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial.
Gheorghiade M; Gattis WA; O'Connor CM; Adams KF; Elkayam U; Barbagelata A; Ghali JK; Benza RL; McGrew FA; Klapholz M; Ouyang J; Orlandi C;
JAMA; 2004 Apr; 291(16):1963-71. PubMed ID: 15113814
[TBL] [Abstract][Full Text] [Related]
12. Effects of tolvaptan add-on therapy in patients with acute heart failure: meta-analysis on randomised controlled trials.
Ma G; Ma X; Wang G; Teng W; Hui X
BMJ Open; 2019 May; 9(4):e025537. PubMed ID: 31048435
[TBL] [Abstract][Full Text] [Related]
13. Tolvaptan add-on therapy in patients with acute heart failure: A systematic review and meta-analysis.
Luo X; Jin Q; Wu Y
Pharmacol Res Perspect; 2020 Jun; 8(3):e00614. PubMed ID: 32500625
[TBL] [Abstract][Full Text] [Related]
14. Immediate administration of tolvaptan prevents the exacerbation of acute kidney injury and improves the mid-term prognosis of patients with severely decompensated acute heart failure.
Shirakabe A; Hata N; Yamamoto M; Kobayashi N; Shinada T; Tomita K; Tsurumi M; Matsushita M; Okazaki H; Yamamoto Y; Yokoyama S; Asai K; Shimizu W
Circ J; 2014; 78(4):911-21. PubMed ID: 24553192
[TBL] [Abstract][Full Text] [Related]
15. Effects of tolvaptan in patients with chronic kidney disease and chronic heart failure.
Katsumata M; Hirawa N; Sumida K; Kagimoto M; Ehara Y; Okuyama Y; Fujita M; Fujiwara A; Kobayashi M; Kobayashi Y; Yamamoto Y; Saka S; Yatsu K; Fujikawa T; Toya Y; Yasuda G; Tamura K; Umemura S
Clin Exp Nephrol; 2017 Oct; 21(5):858-865. PubMed ID: 28190113
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of tolvaptan in acute heart failure patients during long-distance transportation.
Iwata S; Yamaki M; Nishiura T; Nakagawa K; Tokuno S; Sakai H; Okada M
Am J Emerg Med; 2022 Jan; 51():58-63. PubMed ID: 34678574
[TBL] [Abstract][Full Text] [Related]
17. Clinical utility of early use of tolvaptan in very elderly patients with acute decompensated heart failure.
Niikura H; Iijima R; Anzai H; Kogame N; Fukui R; Takenaka H; Kobayashi N
Anatol J Cardiol; 2017 Sep; 18(3):206-212. PubMed ID: 28777097
[TBL] [Abstract][Full Text] [Related]
18. Good response to tolvaptan shortens hospitalization in patients with congestive heart failure.
Kogure T; Jujo K; Hamada K; Saito K; Hagiwara N
Heart Vessels; 2018 Apr; 33(4):374-383. PubMed ID: 29128962
[TBL] [Abstract][Full Text] [Related]
19. Tolvaptan in Patients Hospitalized With Acute Heart Failure: Rationale and Design of the TACTICS and the SECRET of CHF Trials.
Felker GM; Mentz RJ; Adams KF; Cole RT; Egnaczyk GF; Patel CB; Fiuzat M; Gregory D; Wedge P; O'Connor CM; Udelson JE; Konstam MA
Circ Heart Fail; 2015 Sep; 8(5):997-1005. PubMed ID: 26374918
[TBL] [Abstract][Full Text] [Related]
20. Tolvaptan reduces the risk of worsening renal function in patients with acute decompensated heart failure in high-risk population.
Matsue Y; Suzuki M; Seya M; Iwatsuka R; Mizukami A; Nagahori W; Ohno M; Matsumura A; Hashimoto Y
J Cardiol; 2013 Feb; 61(2):169-74. PubMed ID: 23159210
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
